“Prior phase 2/3 studies found that cannabinoids might provide adjunctive analgesia in advanced cancer patients with uncontrolled pain.
To assess adjunctive nabiximols (Sativex®), an extract of Cannabis sativa containing two potentially therapeutic cannabinoids (Δ9-tetrahydrocannabinol and cannabidiol, in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy.
Nabiximols was statistically superior to placebo on two of three quality-of-life instruments at week 3 and on all three at week 5.
The safety profile of nabiximols was consistent with earlier studies.
Although not superior to placebo on the primary efficacy endpoint, nabiximols had benefits on multiple secondary endpoints, particularly in US patients.
Nabiximols might have utility in patients with advanced cancer who receive a lower opioid dose, such as individuals with early intolerance to opioid therapy.”
https://www.ncbi.nlm.nih.gov/pubmed/28923526
http://www.jpsmjournal.com/article/S0885-3924(17)30465-7/fulltext
